Changes in COPD demographics and costs over 20 years

Journal of Medical Economics

Volumn 15, Issue 6, 2012, Pages 1176-1182

  Blanchette, Christopher M ^a   Dalal, Anand A ^b   Mapel, Douglas ^c  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

Chronic obstructive pulmonary disease (COPD); Costs; Epidemiology; Indirect costs

Indexed keywords

PRESCRIPTION DRUG; RESPIRATORY TRACT AGENT;

ABSENTEEISM; ADULT; AGED; AMBULATORY CARE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DRUG COST; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HEALTH SURVEY; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT CARE; PRESCRIPTION; PREVALENCE; PREVENTIVE MEDICINE; RISK FACTOR; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; CONTINENTAL POPULATION GROUPS; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; FEMALE; HEALTH BEHAVIOR; HEALTH SERVICES; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEX DISTRIBUTION; UNITED STATES;

EID: 84869764526     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.713880     Document Type: Article

References (18)

1. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic Obstructive Pulmonary Disease Surveillance - United States, 1971-2000. MMWR 2002;51:116. http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5106a1.htm. Accessed October 17, 2011
2. Hurd SS. International efforts directed at attacking the problem of COPD. Chest 2000;117:336s-8s
3. Global Strategy for Diagnosis, Management, and Prevention of COPD, updated 2008, Global Initiative for Chronic Obstructive Lung Disease. Chapter 2. Burden of COPD. http://www.goldcopd.org/uploads/users/files/GOLDReport- April112011.pdf. Accessed October 17, 2011
4. National Heart, Lung, and Blood Institute. Morbidity and mortality chart book on cardiovascular, lung and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health. http://www.nhlbi.nih.gov/resources/docs/cht-book.htm; 2009. Accessed January 16, 2012
5. Zielinski J, Bednarek M, The Know the Age of your Lung Study Group. Early detection of COPD in a high-risk population using spirometric screening. Chest 2001;119:731-6
6. National Medical Expenditure Survey. Rockville, MD: Agency for Healthcare Research and Quality, 1987. http://www.icpsr.umich.edu/icpsrweb/ICPSR/ studies/9674. Accessed January 16, 2012
7. Medical Expenditure Panel Survey. Rockville, MD: Agency for Healthcare Research and Quality, 2010. http://meps.ahrq.gov/mepsweb/. Accessed January 16, 2012
8. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest 2001;119:344-52
9. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2006. www.goldcopd.com. Accessed January 15, 2012
10. Ware JE, Kosinski M, Turner-Bowker DM, et al. How to score version 2 of the SF-12 Health Survey (with a supplement documenting version 1). Lincoln, RI: QualityMetric Incorporated, 2002
11. Centers for Disease Control and Prevention (CDC). Deaths from chronic obstructive pulmonary disease - United States, 2000-2005. MMWR Morb Mortal Wkly Rep 2008;57:1229-32
12. American Lung Association. Trends in COPD (Chronic Bronchitis and Emphysema): morbidity and mortality. 2011. http://www.lungusa.org/ finding-cures/our-research/trend-reports/copd-trend-report.pdf. Accessed February 2, 2012
13. Historical Inflation. InflationData.com. 2012. http://www.inflationdata. com/ inflation/inflation-rate/historicalinflation.aspx. Accessed January 15, 2012
14. Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. IJCOPD 2010;5:341-9
15. Dalal AA, Shah M, D'Souza AO, et al. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 2011;105:454-60
16. West A, Strom BL, Poole C. Validity of pharmacoepidemiologic drug and diagnosis data. In: Strom BL, Pharmacoepidemiology, 4th edn. John Wiley & Sons, Ltd, West Sussex, England, 2005, p 709-65
17. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58:323-37
18. Dalal AA, St. Charles M, Petersen HV, et al. Cost-effectiveness of combination fluticasone propionate/salmeterol 250/50 mcg versus salmeterol in severe COPD patients. IJCOPD 2010:5:179-87